Background: The study aims to analyze the prescription pattern of SGLT2 inhibitors in patients with metabolic syndrome. These drugs have extensive role in controlling hypertension, hypercholesteremia, obesity other than their primary role in controlling diabetes. Materials and Methods: It was a retrospective data analysis study done at a tertiary care hospital among the metabolic syndrome patients attending medicine OP during July 2023 to February 2024. Results: The data showed that 25% percent of prescribed drugs included SGLT2 inhibitors, which can be further utilized in controlling the comorbid condition. Conclusion: currently, the use of SGLT2 inhibitors have been limited for the prescription of metabolic patients, which can actually be augmented extensively in drug utilization in future.